MTNB - Matinas BioPharma Holdings, Inc.

0.576
-0.028   -4.774%

Share volume: 8,648
Last Updated: 03-05-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.31%

PREVIOUS CLOSE
CHG
CHG%
$0.60
-0.03
-0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
5%
Profitability 0%
Dept financing 3%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-6.87%
1 Month
-2.37%
3 Months
-35.61%
6 Months
-65.51%
1 Year
1.77%
2 Year
121.62%
Key data
Stock price
$0.58
P/E Ratio 
0.00
DAY RANGE
$0.58 - $0.60
EPS 
-$1.79
52 WEEK RANGE
$0.47 - $3.09
52 WEEK CHANGE
$4.35
MARKET CAP 
9.614 M
YIELD 
N/A
SHARES OUTSTANDING 
6.406 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
2.72
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$22,131
AVERAGE 30 VOLUME 
$25,636
Company detail
CEO: Jerome D. Jabbour
Region: US
Website: matinasbiopharma.com
Employees: 30
IPO year: 2017
Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Matinas BioPharma Holdings, Inc. focuses on the discovery and development of various product candidates. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients.

Recent news